Page 142 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 142
Chapter 6a
Implications for patient care:
The subgroup comprising the 6% of patients having a high or high-intermediate aaIPI and a 70% or less ∆SUVmax reduction at I-PET is of interest for testing new therapy strategies in DLBCL
140
